Logotype for Longeveron Inc

Longeveron (LGVN) investor relations material

Longeveron Q3 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Longeveron Inc
Q3 2025 earnings summary4 Nov, 2025

Executive summary

  • Leadership transition with a new interim CEO and board members, focusing on disciplined execution, cash runway extension, and advancing clinical programs for HLHS, Alzheimer's disease, and pediatric dilated cardiomyopathy.

  • Completed full enrollment in pivotal Phase 2b HLHS trial (ELPASO-2/ELPIS II); top-line results expected Q3 2026, with BLA filing targeted for 2027 if successful.

  • Achieved key regulatory milestones for laromestrocel, including Orphan Drug, Fast Track, Rare Pediatric Disease, and RMAT designations for various indications.

  • Discontinued Japan frailty trial in 2024 to focus resources on core programs.

  • Licensing of new stem cell technology and ongoing evaluation of commercial partnerships and M&A opportunities.

Financial highlights

  • Revenue for the nine months ended September 30, 2025, was $0.8M, down 53% from $1.8M in 2024, due to decreased demand in the Bahamas registry trial and contract manufacturing.

  • Net loss for the nine months ended September 30, 2025, was $17.3M, up 45% from $11.9M in 2024, with R&D expenses rising 52% to $9.3M and G&A expenses up 22% to $9.1M.

  • Gross profit for the nine months was $0.5M, down from $1.4M in 2024.

  • Cash and cash equivalents as of September 30, 2025, were $9.2M, with working capital of $5.4M.

  • Accumulated deficit reached $126.9M as of September 30, 2025.

Outlook and guidance

  • Cash runway extended into late Q1 2026 through operational decisions and recent financing; additional capital required to continue as a going concern.

  • Top-line results from pivotal HLHS trial expected in Q3 2026, with BLA submission readiness as a key priority for 2027.

  • Company will seek additional financing through equity, grants, and strategic partnerships; no assurance of future financing at favorable terms.

  • Anticipates increased spending for BLA-enabling activities and clinical trial advancement.

  • Substantial doubt exists about the ability to continue as a going concern without new financing.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Longeveron earnings date

Logotype for Longeveron Inc
Q4 202527 Feb, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Longeveron earnings date

Logotype for Longeveron Inc
Q4 202527 Feb, 2026

The essential earnings season companion

The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Longeveron Inc. is a clinical-stage biotechnology company focused on the development of cellular therapies for aging-related and life-threatening conditions. The company’s lead investigational products are based on allogeneic mesenchymal stem cells (MSCs), which aim to promote tissue repair, reduce inflammation, and enhance immune responses. Longeveron’s research targets indications such as aging-related frailty, cardiovascular diseases, and other chronic conditions. The company is headquartered in Miami, Florida, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage